These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30649752)

  • 1. Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma.
    Carlsson M; Braddock M; Li Y; Wang J; Xu W; White N; Megally A; Hunter G; Colice G
    Drug Saf; 2019 Jun; 42(6):769-784. PubMed ID: 30649752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials.
    Panettieri RA; Sjöbring U; Péterffy A; Wessman P; Bowen K; Piper E; Colice G; Brightling CE
    Lancet Respir Med; 2018 Jul; 6(7):511-525. PubMed ID: 29792288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
    Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
    BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program.
    Panettieri RA; Wang M; Braddock M; Bowen K; Colice G
    Immunotherapy; 2018 Mar; 10(6):473-490. PubMed ID: 29536781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
    Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
    Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
    Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.
    Piper E; Brightling C; Niven R; Oh C; Faggioni R; Poon K; She D; Kell C; May RD; Geba GP; Molfino NA
    Eur Respir J; 2013 Feb; 41(2):330-8. PubMed ID: 22743678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma.
    Baverel PG; White N; Vicini P; Karlsson MO; Agoram B
    Clin Pharmacol Ther; 2018 May; 103(5):826-835. PubMed ID: 28758192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis.
    Zhang Y; Cheng J; Li Y; He R; Pan P; Su X; Hu C
    J Allergy Clin Immunol Pract; 2019; 7(8):2661-2671.e3. PubMed ID: 31152798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.
    Busse WW; Brusselle GG; Korn S; Kuna P; Magnan A; Cohen D; Bowen K; Piechowiak T; Wang MM; Colice G
    Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30442714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.
    Baverel PG; Jain M; Stelmach I; She D; Agoram B; Sandbach S; Piper E; Kuna P
    Br J Clin Pharmacol; 2015 Dec; 80(6):1337-49. PubMed ID: 26182954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaphylaxis to the carbohydrate side chain alpha-gal.
    Platts-Mills TA; Schuyler AJ; Tripathi A; Commins SP
    Immunol Allergy Clin North Am; 2015 May; 35(2):247-60. PubMed ID: 25841549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
    Merola JF; Bagel J; Almgren P; Røpke MA; Lophaven KW; Vest NS; Grewal P
    J Am Acad Dermatol; 2021 Jul; 85(1):71-78. PubMed ID: 33744356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.
    Baverel P; She D; Piper E; Ueda S; Yoshioka T; Faggioni R; Gevorkyan H
    Drug Metab Pharmacokinet; 2018 Jun; 33(3):150-158. PubMed ID: 29622380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute infusion reactions induced by monoclonal antibody therapy.
    Maggi E; Vultaggio A; Matucci A
    Expert Rev Clin Immunol; 2011 Jan; 7(1):55-63. PubMed ID: 21162650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers.
    de Kam PJ; Nolte H; Good S; Yunan M; Williams-Herman DE; Burggraaf J; Kluft C; Adkinson NF; Cullen C; Skov PS; Levy JH; van den Dobbelsteen DJ; van Heumen ELGM; van Meel FCM; Glassner D; Woo T; Min KC; Peeters PAM
    Br J Anaesth; 2018 Oct; 121(4):758-767. PubMed ID: 30236238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody.
    Deniz YM; Gupta N
    Clin Rev Allergy Immunol; 2005 Aug; 29(1):31-48. PubMed ID: 16222082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
    Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.